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Summary: In some randomized clinical trials, patients may die before the measurements of their outcomes. Even
though randomization generates comparable treatment and control groups, the remaining survivors often differ
significantly in background variables that are prognostic to the outcomes. This is called the truncation by death
problem. Under the potential outcomes framework, the only well-defined causal effect on the outcome is within the
subgroup of patients who would always survive under both treatment and control. Because the definition of the
subgroup depends on the potential values of the survival status that could not be observed jointly, without making
strong parametric assumptions, we cannot identify the causal effect of interest and consequently can only obtain
bounds of it. Unfortunately, however, many bounds are too wide to be useful. We propose to use detailed survival
information before and after the measurements of the outcomes to sharpen the bounds of the subgroup causal effect.
Because survival times contain useful information about the final outcome, carefully utilizing them could improve
statistical inference without imposing strong parametric assumptions. Moreover, we propose to use a copula model
to relax the commonly-invoked but often doubtful monotonicity assumption that the treatment extends the survival
time for all patients.
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1. Introduction
In randomized clinical studies, evaluations of the effectiveness of alternative treatments
on a non-mortality outcome such as the health related quality of life (HRQOL) outcome
are often complicated by truncation by death. The motivation of our study comes from
a prostate cancer research (Petrylak et al., 2004), a Southwest Oncology Group (SWOG)
clinical trial, where an interest is to assess the effect on a HRQOL outcome measured at six
months after treatment among advanced refractory prostate cancer patients being treated
with Docetaxel and Estramustine (DE) versus Mitoxantrone and Prednisone (MP). But
some patients died within six months after treatment, and therefore their HRQOL outcomes
were not measured and were not even well-defined. As it is well known, to estimate the
treatment effect on a HRQOL outcome that is truncated by death, a direct comparison
between survivors in two treatment arms could be biased. This is because death serves
as a mechanism of informative censoring given its strong correlation with the HRQOL.
Intuitively, those patients who died would usually have had worse HRQOL outcomes than
those who survived had they somehow been kept alive (Cox et al., 1992). To formulate a well-
defined treatment effect on outcomes truncated by death, we adopt the principal stratification
framework (Frangakis and Rubin, 2002). Based on whether each patient would survive to the
HRQOL outcome measurement under treatment and whether the patient would survive to
the HRQOL outcome measurement under control, subjects are classified into four principal
strata as will be discussed in Section 2.2. The stratum of patients who would survive to
the outcome measurement under both treatment and control are called always survivors.
Following Frangakis and Rubin (2002) and Rubin (2006), we focus on the treatment effect
among the always survivors, also called the survivor average causal effect (SACE), because
they have well-defined HRQOL outcomes under both treatment arms.
Unfortunately, the SACE is not pointly identified without strong and untestable assump-
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tions such as by imposing a full parametric model (Zhang et al., 2009; Frumento et al.,
2012) or by utilizing a substitution variable for the latent survival type (Ding et al., 2011;
Jiang et al., 2016; Ding and Lu, 2017; Wang et al., 2017). Although plausible for the settings
considered by the authors, those assumptions can be too strong to be applied to many general
cases where the parametric constraint is questionable and where a valid substitution variable
is not available. Under weaker assumptions on the degree of selection bias, one can instead
achieve partial identification on the SACE. Zhang and Rubin (2003) derived large sample
bounds on the SACE under ranked average score assumptions, which are the shortest bounds
possible without further assumptions. Long and Hudgens (2013) sharpened the bounds by
using covariates. Yang and Small (2016) extended the ranked average score assumptions to
further utilize survival information at a time point after the measurement of the HRQOL
outcome.
In the previous literature on bounding the SACE, we are aware of two limitations. First,
to shorten the bounds on the SACE without imposing a parametric model, the monotonicity
assumption on the survival status is often invoked with a few exceptions (Zhang and Rubin,
2003; Ding et al., 2011; Wang et al., 2017). The monotonicity assumption states that the
treatment does not cause death compared to the control, meaning that if a subject would die
before the measurement of the HRQOL outcome therefore being truncated under treatment,
the subject would also die before the measurement of the HRQOL outcome had the subject
received the control. This assumption cannot be directly validated, and can be suspicious in
many studies. Taking our motivating prostate cancer study SWOG as an example, although
DE results in longer survival on average (Petrylak et al., 2004), from a clinical point of view,
the monotonicity assumption that no patients could benefit from MP in survival may not
be true since both DE and MP are active treatments. Previous research (Ding et al., 2011)
suggested that the monotonicity assumption was likely to be violated in the SWOG study.
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Second, survival tends to be positively correlated with HRQOL and is informative as a proxy
of health condition, but the previous literature on bounding the SACE utilizes only limited
information of survival. Zhang and Rubin (2003), by imposing the ranked average score
assumptions, utilized the survival information right before the measurement on the HRQOL
outcome, and showed that this information was helpful to sharpen the bounds of the SACE.
The authors derived the bounds with and without imposing the monotonicity assumption.
Yang and Small (2016) showed that using a post measurement time point survival infor-
mation in addition to the survival information right before the measurement could further
improve the bounds on the SACE. However, in practice, more detailed survival information
is often available in studies where patients were followed up for multiple times, such as
the SWOG clinical trial where patients were followed up at three months, six months and
twelve months, respectively. This more detailed survival information can provide additional
information on the health condition of the patients, and therefore, help further improve
the inference on the SACE. In addition, the method the authors developed relied on the
monotonicity assumption, which limited the applicability of the method.
In this paper, under the principal stratification framework, we propose a set of ranked
average score assumptions to incorporate detailed survival information to sharpen the infer-
ence on the SACE in the context of randomized trials, and meanwhile, remove the untestable
and often violated monotonicity assumption on survival. Because only one potential survival
status is observed for each patient, the stratum membership is not observable in general.
With detailed survival information, the four principal strata can be further divided into
many finer ones given the potential values of the survival time, thereby introducing additional
complications to inference. To address the issue of latent stratum membership, assumptions
on the joint distribution of potential survivals are necessary. In our approach, we model the
joint distribution of the two potential survival times under treatment and control through
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a copula (Nelsen, 2006). Copulas provide a flexible way for modeling dependencies and
have been used to model the joint distributions of potential outcomes in various contexts
(Bartolucci and Grilli, 2011; Ma et al., 2011; Conlon et al., 2017). Using a copula model,
we avoid the monotonicity assumption, and characterize the association between the two
potential survival times by a single copula parameter. For each fixed value of the copula
parameter, deriving the bounds on the SACE under the proposed ranked average score
assumptions defines a linear programming problem. The final bounds on the SACE can then
be obtained by varying the value of the copula parameter in a plausible range. We apply
our proposed method to the SWOG study. By utilizing detailed survival information, we are
able to substantially narrow the bounds on the SACE for the effect of DE versus MP.
2. Notation and Assumptions
2.1 Notation: potential and observed outcomes
We consider two-arm randomized experiments and adopt the potential outcomes framework
to define causal effects. We let Di be the binary treatment for the i-th subject (i = 1, ..., n);
we call level 1 “the treatment” and level 0 “the control”. LetD denote the vector of treatment
assignment indicators for all subjects. We use Si(d) to represent the discretized potential
survival time of subject i from the initiation of the treatment that would be observed under
treatment assignment d which could be measured, for instance, by month, by year, etc.
Assuming that there are K follow-ups at time points s1, s2, ..., sK , respectively from the
initiation of the treatment, then the values that Si(d) can take are s0, s1, ..., sK where s0 = 0.
Take the SWOG study as an example, subjects were followed up three times, and therefore
K = 3. Si(d) will take a value 0 (s0 = 0) if under the treatment assignment d patient i
would die before the first follow-up time three months, 3 (s1 = 3) if patient i would die
between three months and the second follow up time six months, 6 (s2 = 6) if patient i
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would die between six months and the last follow up time twelve months, and 12 (s3 = 12) if
patient i would still be alive at twelve months. We use Yi(d) to denote the binary potential
HRQOL outcome of subject i that would be observed under treatment assignment d. We
consider HRQOL outcome measured at a fixed time point, the T th follow-up (T < K), and
therefore for subjects who would die before time point sT , i.e., those with Si(d) < sT , their
potential HRQOL outcomes Yi(d)’s are not defined. Throughout this paper, we let level 1 of
the HRQOL outcome be worse than level 0. We use Si and Yi to denote respectively subject
i’s observed survival time and observed HRQOL outcome.
2.2 Assumptions and the parameter of interest
Under the stable unit treatment value assumption (SUTVA), there is only a single version of
each treatment level and there is no interference between subjects. Therefore, we can write
Si(d) and Yi(d) as Si(di) and Yi(di), respectively. Moreover, the subjects can be classified
into four latent groups based on the joint values of potential survival status at the HRQOL
outcome measurement time sT under treatment and under control. Let Ui denote subject
i’s latent group, which is defined as: Ui = always survivor if Si(1) > sT and Si(0) > sT ,
meaning that the subject would survive at least to the time point of measurement under
both treatment and control; Ui = protected if Si(1) > sT and Si(0) < sT , meaning that the
subject would survive at least to the time point of measurement only under treatment; Ui =
harmed if Si(1) < sT and Si(0) > sT , meaning that the subject would survive at least to the
time point of measurement only under control; and Ui = never survivor if Si(1) < sT and
Si(0) < sT , meaning that the subject would die before the time point of measurement under
both treatment and control. Among those four groups, the always survivors constitute the
only group for which both Yi(1) and Yi(0) are well defined at time sT . Thus the treatment
effect on the HRQOL outcome is only well defined for always survivors (Frangakis and Rubin,
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2002; Rubin, 2006), that is, the survivor average causal effect:
SACE = E{Yi(1)− Yi(0) | Si(1) > sT , Si(0) > sT}. (1)
Assumption 1: The treatment Di is independent of the potential outcomes Si(1), Si(0),
Yi(1) and Yi(0).
In randomized studies such as SWOG, the ignorable treatment assignment assumption is
guaranteed by design.
The following two assumptions compare two groups of subjects: G1 = {i | Si(0) =
st0 , Si(1) = st1} andG2 = {i | Si(0) = st′0 , Si(1) = st′1}, where t0, t1, t
′
0, t
′
1 ∈ {0, 1, 2, ..., T, ..., K}.
Assumption 2: (i) When both groups G1 and G2 have well defined Yi(1) (i.e., t1 > T and
t′1 > T ), if st1 > st′1 and st0 > st′0 , then, P{Yi(1) = 1 | Si(0) = st0 , Si(1) = st1} 6 P{Yi(1) =
1 | Si(0) = st′
0
, Si(1) = st′
1
};
(ii) When both groups G1 and G2 have well defined Yi(0) (i.e., t0 > T and t
′
0 > T ), if
st0 > st′0 and st1 > st′1 , then, P{Yi(0) = 1 | Si(0) = st0 , Si(1) = st1} 6 P{Yi(0) = 1 | Si(0) =
st′
0
, Si(1) = st′
1
}.
Assumption 2 compares the HRQOL outcomes between two groups of subjects where one
group’s survival times under treatment and control are both longer than or equal to those
of the other group. The probability of a worse HRQOL outcome for the group with longer
survival times is not higher than that for the other group, recalling that level 1 of the HRQOL
outcome is worse than level 0.
Assumption 3: (i) When both groups G1 and G2 have well defined Yi(1) (i.e., t1 > T
and t′1 > T ), if st1 > st′1 , st0 < st′0 , but st1 − st′1 > st′0 − st0 , then, P{Yi(1) = 1 | Si(0) =
st0 , Si(1) = st1} 6 P{Yi(1) = 1 | Si(0) = st′0 , Si(1) = st′1};
(ii) When both groups G1 and G2 have well defined Yi(0) (i.e., t0 > T and t
′
0 > T ), if
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st0 > st′0 , st1 < st′1 , but st0 − st′0 > st′1 − st1 , then P{Yi(0) = 1 | Si(0) = st0 , Si(1) = st1} 6
P{Yi(0) = 1 | Si(0) = st′
0
, Si(1) = st′
1
}.
Assumption 3(i) compares the HRQOL outcome under treatment between two groups of
subjects where one group has longer survival under treatment but shorter survival under
control than the other group. If one group’s additional length of survival under treatment
compared to the other group is no less than their reduced length of survival under control,
Assumption 3(i) says that the probability of the worse HRQOL outcome under treatment for
the group with longer survival under treatment is not higher than that for the other group.
Assumption 3(ii) is the analogous assumption on the HRQOL outcome under control.
Assumptions 2 and 3 are our generalized ranked average score assumptions which utilize the
survival information on multiple time points. They are plausibly satisfied in many HRQOL
studies because survival is often positively related to the HRQOL. Therefore, it is reasonable
to assume that the potential survival time is positively associated with a better potential
HRQOL outcome, and is more predictive to the potential HRQOL outcome under the same
treatment condition than under a different treatment condition. In particular, Assumption
2 says that the subjects with longer survivals under both treatment and control tend to
be healthier on average, and therefore, are less likely to develop the bad HRQOL outcome.
Assumption 3(i) says that for subjects’ health condition under treatment, survival under
treatment is a better predictor of the HRQOL than survival under control. Therefore, even
if one group of subjects live shorter than the other group under control, as long as they
live much longer under treatment, they are healthier under treatment and are less likely
to develop bad HRQOL outcome under treatment. Similarly, for subjects’ health condition
under control, Assumption 3(ii) says that it is survival under control is a better predictor.
Remark 1. Our generalized ranked average score assumptions on the HRQOL become
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intuitive if we consider the following generalized linear models:
P{Yi(1) = 1 | Si(0) = st0 , Si(1) = st1} = g
−1(β − β0st0 − β1st1),
P{Yi(0) = 1 | Si(0) = st0 , Si(1) = st1} = g
−1(γ − γ0st0 − γ1st1).
If g(x) = log(x), then e−βd and e−γd are the conditional relative risks of Si(d) on the
treatment and control potential HRQOL for d = 0, 1. The models above imply that
log
P{Yi(1) = 1 | Si(0) = st0 , Si(1) = st1}
P{Yi(1) = 1 | Si(0) = st′
0
, Si(1) = st′
1
}
= −β0(st0 − st′0)− β1(st1 − st′1), (2)
log
P{Yi(0) = 1 | Si(0) = st0 , Si(1) = st1}
P{Yi(0) = 1 | Si(0) = st′
0
, Si(1) = st′
1
}
= −γ0(st0 − st′0)− γ1(st1 − st′1). (3)
If β0, β1, γ1, γ0 > 0, then Assumption 2 holds. If β1 > β0, i.e., the conditional relative risk of
Si(1) on Yi(1) is larger than Si(0), then Assumption 3(i) holds. If γ0 > γ1, i.e., the conditional
relative risk of Si(0) on Yi(0) is larger than Si(1), then Assumption 3(ii) holds.
If g(x) = x, then −βd and −γd are the partial regression coefficients of Si(d) on the
treatment and control potential HRQOL for d = 0, 1. Then the right-hand sides of (2) and
(3) are the corresponding comparisons of the conditional probabilities on the risk difference
scale. If β0, β1, γ1, γ0 > 0, then Assumption 2 holds. If β1 > β0, i.e., the partial regression
coefficient of Si(1) on Yi(1) is larger than Si(0), then Assumption 3(i) holds. If γ0 > γ1, i.e.,
the partial regression coefficient of Si(0) on Yi(0) is larger than Si(1), then Assumption 3(ii)
holds.
Note that the models in this remark are used to aid interpretations, and our method does
not need to invoke them.
Zhang and Rubin (2003), hereafter ZR, proposed ranked average score assumptions to
utilize the survival information on a single time point, i.e., the survival status when the
HRQOL outcome was measured. Their assumptions say that when assigned to treatment,
the risk of the worse HRQOL outcome for always survivors is not higher than that for the
protected; and when assigned to control, the risk of the worse HRQOL outcome for always
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survivors is not higher than that for the harmed. Mathematically, ZR assumed,
P{Yi(1) = 1 | Si(1) > sT , Si(0) > sT} 6 P{Yi(1) = 1 | Si(1) > sT , Si(0) < sT}, (4)
P{Yi(0) = 1 | Si(1) > sT , Si(0) > sT} 6 P{Yi(0) = 1 | Si(1) < sT , Si(0) > sT}. (5)
Different from our assumptions, ZR used only the survival information at the time point of
the measurement of the HRQOL outcome. However, detailed survival information contains
additional information on the health condition of the subjects, which can help further sharpen
the inference on the SACE. Moreover, detailed survival information creates strata finer than
the four principal strata, and the comparisons among those finer strata result in more
plausible assumptions than the coarse comparisons among the four principal strata. For
example, consider the SWOG study of the effect of DE (treatment) versus MP (control) on
the HRQOL at six months described in the introduction, where patients were followed up
at three months, six months and twelve months. Let us compare the following two groups’
HRQOL outcomes. The first group consists of patients who would die shortly after six months
no matter being treated by DE or MP, i.e., Si(1) = Si(0) = 6. The second group consists of
patients who would survive more than twelve months no matter being treated by DE or MP,
i.e., Si(1) = Si(0) = 12. Apparently, the first group subjects’ health conditions at six months
are much worth than those of the second group because the first group would die shortly
after six months no matter being treated by DE or MP. Therefore, it’s reasonable to assume
that the first group’s risk of bad HRQOL outcome is not lower than that for the second group
as implied by our Assumption 2. However, ZR did not provide a comparison between two
groups like those. For another example, ZR assumed that the protected, on average, had worse
HRQOL outcomes than always survivors under treatment. In contrast, our Assumption 3
assumes that some particular subgroups of always survivors, on average, have worse HRQOL
outcomes than some particular subgroups of the protected under treatment, which are more
reasonable assumptions for many HRQOL studies given more survival information. Let’s still
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consider the SWOG study and compare the following two groups’ HRQOL outcomes under
DE. The first group again consists of patients who would die shortly after six months no
matter being treated by DE or MP, i.e., Si(1) = Si(0) = 6. The second group consists of
patients who would survive more than twelve months if being treated by DE and would die
shortly after three months if being treated by MP, i.e., Si(1) = 12, and Si(0) = 3. Patients
respond differently to different treatments. Although the patients in the second group do not
respond to MP as those patients in the first group, they respond to DE much better than
the patients in the first group. Thus, it is reasonable to assume that when being treated by
DE, the second group of patients, a subgroup of the protected, are likely to be less sick at
six month, and therefore, their risks of bad HRQOL outcome are not higher than those for
the first group of patients, a subgroup of always survivors.
Yang and Small (2016), hereafter YS, extended ZR’s ranked average score assumptions
by utilizing a post measurement time point survival information. Their assumptions could
be viewed as a simple version of our generalized ranked average score assumptions with
two follow-up time points and with monotonicity constraints on the survival. The authors
considered a scenario where the subjects were followed up twice (K = 2) and their HRQOL
outcomes were measured at the first follow up time point (T = 1). Besides the SUTVA and
Ignorability assumptions, the monotonicity assumption was imposed to restrict the possible
combinations of the values of Si(1) and Si(0). Mathematically, the monotonicity assumption
states that, Si(1) > Si(0). As we discussed in the introduction, this assumption is strong and
often suspicious. Assumptions 5 to 7 in YS are exactly the same as our generalized ranked
average score assumptions (i.e., Assumptions 2 and 3) in this special case of K = 2, T = 1
and equal lengths of follow-up intervals (i.e., s2−s1 = s1) or longer second follow-up interval
than the first (i.e., s2 − s1 > s1), without considering subjects whose survival would be
harmed by the treatment. Compared with YS, our assumptions are more conservative in the
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case of longer first follow-up interval than the second (i.e., s2−s1 < s1). Consider two groups
of patients where the first group consists of patients who would survive to the first follow-up
time point s1 under both treatment and control (i.e., patients with Si(1) = Si(0) = s1),
and the second group consists of patients who would survive at least to the second follow-
up time point s2 under treatment however would die even before the first follow-up time
point (i.e., patients with Si(1) = s2, Si(0) = 0). YS always assume that the second group’s
risk of bad HRQOL outcome under treatment is not higher than that for the first group;
in contrast, we only make this assumption when the second group’s additional length of
survival under treatment compared to the first group (i.e., s2 − s1) is no less than their
reduced length of survival under control (i.e., s1). In addition, the derived bounds in YS
rely on the monotonicity assumption, which may or may not cover the true effect when the
monotonicity is violated. See the numerical examples in the Supplementary Materials.
3. Derivation of Bounds Under a Copula Model
In this section, we derive large sample bounds for the SACE under Assumptions 1–3 assuming
that the observable joint distribution of (Di, Si, Yi) is known.
3.1 Bounds given the joint distribution of Si(1) and Si(0)
Define qt1t0d = P{Yi(d) = 1 | Si(1) = st1 , Si(0) = st0}. Define pt1t0 = P{Si(1) = st1 , Si(0) =
st0} as the proportion of the fine stratum that consists of patients who would survive to time
st1 (i.e., t1-th follow-up) under treatment and st0 (i.e., t0-th follow-up) under control. In this
subsection, we assume that the pt1t0 ’s are known. In terms of the fine strata, the SACE is:
SACE = E{Yi(1)− Yi(0) | Si(1) > sT , Si(0) > sT}
= P{Yi(1) = 1 | Si(1) > sT , Si(0) > sT} − P{Yi(0) = 1 | Si(1) > sT , Si(0) > sT}
=
∑K
t1=T
∑K
t0=T
(qt1t01 − qt1t00)pt1t0∑K
t1=T
∑K
t0=T
pt1t0
. (6)
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Meanwhile, under Assumption 1, P (Yi = 1, Si = st | Di = d) = P{Yi(d) = 1, Si(d) = st}.
Therefore, the observable distribution P (Yi, Si | Di) is a mixture distribution of potential
outcomes of fine strata as shown in the following identities:
P (Yi = 1, Si = st0 | Di = 0) =
K∑
t1=0
pt1t0qt1t00, for ∀t0 > T, and (7)
P (Yi = 1, Si = st1 | Di = 1) =
K∑
t0=0
pt1t0qt1t01, for ∀t1 > T. (8)
If we hypothetically know the proportions of each fine stratum pt1t0 , then the bounds for the
SACE could be obtained by solving a linear programming problem with objective function
(6), subject to the linear equality constraints (7) and (8), the linear inequality constraints
(9) that all the probabilities qt1t0d’s are bounded between 0 and 1,
0 6 qt1t0d’s 6 1, (9)
and the linear inequality constraints (10) and (11) imposed by Assumptions 2 and 3:
qt1t01 6 qt′1t′01, for all t1 > t
′
1 > T, st1 + st0 > st′1 + st′0 , (10)
qt1t00 6 qt′1t′00, for all t0 > t
′
0 > T, st1 + st0 > st′1 + st′0 . (11)
3.2 A copula model
Although the marginal distributions of the potential survival times, P{Si(1) = st} and
P{Si(0) = st} are observable, their joint distribution is not. Therefore, the proportions of
fine strata pt1t0 ’s are not identified without further assumptions. To capture the dependence
between the two potential survival times, we propose to use the copula. We assume that
the joint distribution of these intermediate outcomes follows a Plackett copula (Plackett,
1965), where the degree of association is measured by a single parameter. Let Fd(·) be the
marginal distribution function for the random variable Si(d) with Fd(st) = P{Si(d) 6 st}
(d = 0, 1). The joint distribution function F (st1 , st0) of Si(1) and Si(0) linked by a Plackett
copula is given by Cφ(F1(st1), F0(st0)), where C1(u, v) = uv when φ = 1, and Cφ(u, v) =
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{1+(φ−1)(u+v)}−[{1+(φ−1)(u+v)}2−4φ(φ−1)uv]1/2
2(φ−1)
when φ > 0 and φ 6= 1. The parameter φ measures
the association between Si(1) and Si(0), and the Spearman correlation coefficient ρ is a
monotonic function of φ: ρ = φ+1
φ−1
− 2φ log φ
(φ−1)2
. Therefore, Si(1) and Si(0) are independent for
φ = 1, negatively associated for φ < 1, and positively associated for φ > 1. Since the survival
times of patients under both treatment arms are highly dependent on their underlying health
status, it is reasonable to assume that patients who live longer under one treatment arm are
more likely to live longer under the other, implying that φ > 1 (i.e., ρ > 0).
For a fixed φ, the pt1t0 ’s could be calculated based on the joint distribution function,
F (st1, st0) = Cφ(F1(st1), F0(st0)). Then given the values of the pt1t0 ’s, the bounds for the
SACE can be obtained by solving the linear programming problem described in Section 5.
The final bounds for the SACE will be constructed by varying the value of φ on a suitable
grid and obtaining the bounds for each value of φ. The final lower bound will then take the
value of the smallest lower bound among all the lower bounds, and the final upper bound
will take the value of the largest upper bound among all the upper bounds. Alternatively,
we can view φ as a sensitivity parameter, and draw conclusions at different values of φ.
We give two numerical examples in the Supplementary Materials to show the improvement
of our approach over ZR’s and the potential bias of YS’s when monotonicity does not
hold. Although the intuition is overwhelming that our method will lead to narrower bounds
than ZR’s in many cases, it is technically challenging to give a formal proof. Even under
monotonicity, YS did not give a formal proof of improvement over ZR although in most
cases the improvement is apparent.
4. Statistical Inference Accounting for Sampling Variability
The bounds derived in the previous section are large sample bounds, where we assume
that the joint distribution of (Yi, Si) under each treatment arm is known. However, in
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practice, we need to account for the sampling uncertainty in statistical inference. Because our
bounds are results of a linear programming problem, they will be in the form of intersection
(i.e., the lower/upper bound takes the maximum/minimum a collection of functionals). The
maximum and minimum operators involved in the intersection bounds generate significant
complications for both estimation and inference from a frequentist perspective. Most methods
(e.g. Chernozhukov et al., 2013) focusing on asymptotic properties may not have desirable
finite sample properties as investigated by Yang and Small (2016). A recent method proposed
by Jiang and Ding (ress) requires explicit forms of the bounds. To avoid these difficulties in
frequentists’ inference, we adopt a Bayesian approach to conduct inference by deriving the
exact credible intervals for the bounds. The Bayesian approaches are being increasingly
adopted in partially identified models (Gustafson and Greenland, 2009; Scharfstein et al.,
2011; Mealli and Pacini, 2013; Gustafson, 2015).
Suppose that the subjects are followed up to time point K. Let us define parameter vectors
pid = (pi0d, pi1d, ..., piKd) for d = 0, 1 where pitd = P{Si(d) = st}. Given the value of the copula
parameter φ, the joint probability for survival times under treatment and control is, pt1t0 =
Cφ(F1(st1), F0(st0))−Cφ(F1(st1−1), F0(st0))−Cφ(F1(st1), F0(st0−1))+Cφ(F1(st1−1), F0(st0−1)),
where Fd(st) =
∑j=t
j=0 pijd, and Fd(s−1) is defined as 0 for d = 0, 1. We define parameters
αtd = P{Y (d) = 1 | S(d) = st} for d = 0, 1 and t = T, T + 1, ..., K. Given parameters
pid’s and αtd’s, the joint probability of survival and HRQOL outcomes under each treatment
arm is, P{Y = 1, S = st | D = d} = P{Y (d) = 1, S(d) = st} = pitdαtd, for d = 0, 1
and t = T, T + 1, ..., K. We further define compatible region to be the region of parameters
constrained by Assumptions 1–3, i.e.,
Compatible Region ={pi0,pi1, αtd’s (d = 0, 1, t = T, T + 1, ..., K) | there are feasible solutions
qt1t01’s (T 6 t1 6 K, 0 6 t0 6 K) and qt1t00’s (0 6 t1 6 K, T 6 t0 6 K)
to the linear constraints (7)− (11)defined in Section 3.1} (12)
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Prior to observing any data, we assume that the pid’s are independent and follow truncated
Dirichlet distributions with all parameters being 1, i.e., f(pid) ∝ I(Compatible Region) ·
Dirichlet(1, ..., 1), where I(·) is the indicator function taking on the value 1 if the statement
is true and 0 otherwise. Similarly, we assume that the αtd’s are independent and follow trun-
cated Beta distributions with all parameters being 1, i.e., f(αtd) ∝ I(Compatible Region) ·
Beta(1, 1). The posterior distributions of the pid’s and αtd’s can be derived analytically
according to the priors and the likelihood. As an illustration, details on the posterior distri-
butions calculation are provided for the SWOG study in Section 5.
To find the corresponding joint posteriors of the bounds given the value of the copula
parameter φ, we simulate from the posterior distributions of the pid’s and αtd’s, and perform
the linearly constrained optimizations to obtain the lower and upper bounds on the SACE
for each simulation. Credible intervals for the bounds are not unique. A 100(1−α)% credible
interval for the bounds on the SACE would be any interval where there is a 100(1 − α)%
posterior probability that the bounds (i.e., both the lower and upper bounds) fall within.
Among all the 100(1 − α)% credible intervals for the bounds on the SACE given the value
of φ, we choose the one with the shortest length by a numerical search.
5. Application to the Southwest Oncology Group Study
The data previously analyzed by Ding et al. (2011) contain 487 androgen-independent prostate
cancer patients enrolled in the Southwest Oncology Group (SWOG) trial between 1999
and 2003, who were randomized to receive either Docetaxel and Estramustine (DE) or
Mitoxantrone and Prednisone (MP). We view the patients who received DE as the treatment
group (Di = 1), and the patients who received MP as the control group (Di = 0). Let Yi = 1
if there was a reduction in patient i’s HRQOL six months after treatment compared to his
HRQOL at baseline (i.e., a worse HRQOL outcome), and Yi = 0 otherwise. If the patient
died before six months after treatment, the HRQOL level would not be measured and Yi
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will be undefined. Note that we dichotomize the continuous HRQOL measurement to be a
binary outcome indicating its reduction compared to its baseline. Although it might cause
loss of information, this dichotomized outcome is a meaningful measure of the efficacy of
the treatment. Moreover, for statistical inference of this binary outcome, we do not need to
impose any modeling assumptions in contrast to the original continuous outcome.
As described in Section 2, Si takes values s0 = 0, s1 = 3, s2 = 6 or s3 = 12 for
death before three months, between three months and six months, between six months and
twelve months, or after twelve months, respectively. The corresponding T for the Southwest
Oncology Group study equals 2, and the correspondingK equals 3. Among the patients, there
are 135 of them have missing measurements for their HRQOL although survived beyond six
months. In our analysis, we assume that Yi is missing at random given survival Si and the
treatment assignmentDi, and therefore, we can ignore the missing data model in the Bayesian
analysis. We set the priors to be independent and non-informative as described in Section 4,
f(pi1,pi0, α21, α31, α20, α31) ∝ I(Compatible Region). Let Nytd =
∑n
i=1 I(Yi = y, Si = st, Di =
d) for y = 0, 1, t = 2, 3 and d = 0, 1, Utd =
∑n
i=1 I(Yi undefined, Si = st, Di = d) for t = 0, 1
and d = 0, 1, and let Mtd =
∑n
i=1 I(Yi missing, Si = st, Di = d) for t = 2, 3 and d = 0, 1.
Under the missing at random assumption, the posterior density is
f(pi1,pi0, α21, α31, α20, α30 | Y ,S,D)
∝ I(Compatible Region) · piU0101 · pi
U11
11 · pi
M21+N121+N021
21 · pi
M31+N131+N031
31
· piU0000 · pi
U10
10 · pi
M20+N120+N020
20 · pi
M30+N130+N030
30
· αN12121 · (1− α21)
N021 · αN13131 · (1− α31)
N031 · αN12020 · (1− α20)
N020 · αN13030 · (1− α30)
N030 ,
where Y , S, and D are the observed vectors of the HRQOL outcomes, survival times and
treatment assignment indicators for all subjects. Therefore, the posterior distributions of
pi1 and pi0 are Dirichlet with parameters (U01 + 1, U11 + 1,M21 + N121 + N021 + 1,M31 +
N131 + N031 + 1) and (U00 + 1, U10 + 1,M20 + N120 + N020 + 1,M30 + N130 + N030 + 1),
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respectively, and the posterior distributions of α21, α31, α20, α30 are Beta with parameters
(N121+1, N021+1), (N131+1, N031+1), (N120+1, N020+1), (N130+1, N030+1), respectively,
all truncated within the compatible region. Truncation could be done by simulating from
the un-truncated distributions and rejecting the simulations without feasible solutions to the
linear constrained optimization problem. The details of the optimization problem we solve
for the SWOG study are presented in the Supplementary Materials.
Table 1 compares the estimated bounds and the 95% credible intervals under the following
two sets of assumptions: (i) Assumptions 1–3, and (ii) Assumptions 1 with ZR’s ranked
average score assumptions (4) and (5). The point estimates of the lower and upper bounds
are reported based on their posterior medians, and the posterior distributions of the bounds
under (ii) are obtained similarly with non-informative Beta priors on parameters P{Si(d) >
6}’s and P{Yi(d) = 1 | Si(d) > 6}’s for d = 0, 1. According to the results under the set
of assumptions (i), with a moderately small correlation between the two potential survival
times under DE and MP, (e.g., ρ > 0.2), among the patients with androgen-independent
prostate cancer who would survive to at least six months under both DE and MP, DE would
help reduce the risk of bad HRQOL by 0.8 percent to 9.9 percent. Given the facts that the
two potential survival times and two potential HRQOL outcomes are highly dependent on
subjects’ underlying health status, and that the correlation between the potential HRQOL
outcome and potential survival time under DE is 0.22, ρ > 0.2 is probably a plausible
and conservative assumption on the correlation between the two potential survival times
under DE and MP. These bounds are about 40% shorter and are also more informative
than the bounds obtained by utilizing only the survival information at the time point of
measurement, which estimates that the effect of DE is somewhere between reducing the risk
of bad HRQOL outcome by 13.0 percent and increasing the risk by 2 percent compared
to MP. Unfortunately, due to the small sample size and missing data, all the 95% credible
1
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0
0
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0
0
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Table 1
Results for the SWOG study comparing our general ranked average score assumptions with ZR’s ranked average score assumptions.
ρ log(φ) Estimated Bounds Relative Length 95% Credible Interval Relative Length
0.0000 0.000 [−0.110, 0.005] 0.764 [−0.226, 0.128] 0.889
0.1000 0.301 [−0.105,−0.002] 0.684 [−0.222, 0.116] 0.850
0.2000 0.607 [−0.099,−0.008] 0.602 [−0.216, 0.106] 0.811
0.3000 0.926 [−0.092,−0.015] 0.515 [−0.204, 0.103] 0.770
0.4000 1.264 [−0.085,−0.020] 0.428 [−0.194, 0.095] 0.727
0.5000 1.632 [−0.077,−0.025] 0.346 [−0.187, 0.086] 0.685
0.6000 2.049 [−0.070,−0.029] 0.274 [−0.180, 0.080] 0.654
0.7000 2.545 [−0.065,−0.031] 0.224 [−0.174, 0.078] 0.633
0.8000 3.189 [−0.062,−0.033] 0.191 [−0.167, 0.079] 0.620
0.9000 4.191 [−0.059,−0.037] 0.148 [−0.168, 0.073] 0.606
0.9900 7.110 [−0.053,−0.042] 0.072 [−0.162, 0.069] 0.582
0.9990 9.773 [−0.052,−0.043] 0.056 [−0.161, 0.069] 0.578
0.9999 12.331 [−0.052,−0.043] 0.056 [−0.161, 0.069] 0.578
ZR [−0.130, 0.020] 1.0000 [−0.241, 0.157] 1.0000
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intervals cover 0, indicating that there is not enough evidence to conclude that DE improves
the HRQOL outcome among androgen-independent prostate cancer patients who would be
able to survive to at least six months under both treatments.
To evaluate the sensitivity of the proposed approach to the choice of the type of copula,
we also conducted the analysis using the Gaussian copula. The results are very close. For
instance, with a correlation ρ > 0.2 between the two potential survival times under DE
and MP, under the Gaussian copula, the estimated bounds are [−0.098,−0.008] (compared
to [−0.099,−0.008] under the Plackett copula) with a 95% credible interval [−0.216, 0.107]
(compared to [−0.216, 0.106] under the Plackett copula). To save space, the description of
the Gaussian copula and the detailed results are presented in the Supplementary Materials.
6. Discussion
Our approach can also be applied to stratified randomized trials where strata are created
based on prognostic factors and randomization is conducted within each stratum. In these
settings, we can weaken our assumptions by requiring them to hold in each stratum. Each
stratum specific SACE can be bounded, and the overall bounds on the SACE will then be
obtained as a weighted average of stratum specific SACE’s with weights proportional to the
sizes of strata measured by the numbers of always survivors (Freiman and Small, 2014).
We focused on binary outcomes which allow for obtaining nonparametric bounds of the
SACE. If the original outcome Y ∗ is continuous and dichotomization will lose information,
we can consider applying our method to estimate SACE on Y = I(Y ∗ > y) at each point of
y, or imposing additional modeling assumptions on Y ∗. We leave this to future research.
In our analysis of the SWOG data, we focus on the patients’ HRQOL outcome measured
at six months after initiation of the treatment. However, patients’ HRQOL outcomes were
measured repeatedly in this study at each follow-up time point, namely, three months, six
months and twelve months. Using the current approach, one would conduct separate analyses
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on the SACE’s for the HRQOL outcomes measured at different time points, which is not
ideal to study the change in the SACE over time. How to incorporate the information from
repeated measurements of the HRQOL outcomes requires further research.
Subject matter knowledge is necessary to judge the plausibility of our assumptions because
they could not be validated by the observable data. We expect that our approach could be
widely applied to HRQOL outcomes because patients surviving longer tend to be healthier,
and patients’ health conditions under one arm tend to be better predicted by their survival
lengths under the same arm than that under a different arm. However, in studies where
the relationship between the time to truncation and the outcome of interest is not clear,
our assumptions could be suspicious. Consider the causal effect of a job-training program
on participants’ wages that are potentially truncated by unemployment. For some subjects,
longer time to get employed may indicate their being less competitive in the job market,
and therefore, is associated with lower wages. However, for some subjects that are very
competitive and can afford longer unemployment, they may decline some job opportunities
with low wages, and therefore, longer time to get employed is associated with higher wages. In
such a case, our assumptions may not apply, and alternative assumptions should be invoked
to sharpen the inference.
7. Supplementary Materials
Numerical examples referenced in Section 3.2, details on the optimization problem and
sensitivity analysis for the SWOG study referenced in Section 5, original data and source
code can be found at the Biometrics website on Wiley Online Library.
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Supplementary Material
8. Numerical Examples
8.1 Numerical example showing improvements
Consider a hypothetical study where subjects are followed up four times (K = 4) at time
points 1, 2, 3, and 4 with equal follow-up intervals and the HRQOL outcome is measured
at the second follow-up (T = 2). We set the marginal distributions pitd = P{S(d) = st} for
t = 0 to 4 and d = 0, 1 as follows:
pi01 = 0.15, pi11 = 0.25, pi21 = 0.20, pi31 = 0.25, pi41 = 0.15,
pi00 = 0.15, pi10 = 0.15, pi20 = 0.30, pi30 = 0.15, pi40 = 0.25.
Given the marginal distributions, their joint distribution is specified by a Plackett copula
with φ = 7.76, corresponding to a Spearman correlation ρ = 0.6. The underlying risks
of developing the bad HRQOL outcome under treatment and under control for each fine
stratum are described in Table 2.
Table 2
Risks of the bad HRQOL outcome for each fine stratum with Si(1) = t1 and Si(0) = t0 under treatment (qt1t01) and
under control (qt1t00) in the numerical example in Section 1.1. The risks are presented in the form of qt1t01(qt1t00),
with “−” indicating that the corresponding risk is not defined.
❅
❅
❅
❅
❅
t1
t0
0 1 2 3 4
0 − (−) − (−) − (0.60) − (0.55) − (0.45)
1 − (−) − (−) − (0.55) − (0.50) − (0.40)
2 0.80 (−) 0.75 (−) 0.75 (0.50) 0.70 (0.45) 0.65 (0.35)
3 0.75 (−) 0.70 (−) 0.70 (0.50) 0.65 (0.45) 0.60 (0.35)
4 0.65 (−) 0.60 (−) 0.60 (0.45) 0.55 (0.40) 0.50 (0.30)
In the above setup, SACE = 0.210, meaning that the treatment increases the risk of the
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bad HRQOL outcome by 0.210 among patients who will survive at least to time point 2
under both treatment arms.
Suppose that we have an infinite sample. Under Assumption 1, we would observe the values
of pitd’s since pitd = P (Si = st | Di = d), and would observe the joint distribution of Yi and
Si in each treatment arm,
P (Yi = 1, Si = 2 | Di = 1) = 0.146, P (Yi = 1, Si = 3 | Di = 1) = 0.163,
P (Yi = 1, Si = 4 | Di = 1) = 0.079, P (Yi = 1, Si = 2 | Di = 0) = 0.157,
P (Yi = 1, Si = 3 | Di = 0) = 0.068, P (Yi = 1, Si = 4 | Di = 0) = 0.084.
Table 3 presents the bounds for the SACE under Assumptions 1–3 as a function of the
Spearman correlation coefficient ρ. The bounds get tighter as ρ increases. This reflects the
fact that with larger ρ, there is less uncertainty in each subject’ stratum membership when
one of the two potential survival status is observed. With no prior information on ρ and by
conservatively assuming that ρ > 0, we obtain the bounds for the SACE as [0.118, 0.299],
showing that the treatment increases the risk of the bad HRQOL outcome.
In contrast, if we utilize only the survival information at the time point of the HRQOL
outcome measurement, under Assumptions 1 with ZR’s ranked average score assumptions
(4) and (5), the bounds on the SACE are [−0.147, 0.647]. Based on these bounds, we would
not know whether or not the treatment increases the risk of the bad HRQOL outcome even
though the true value of the SACE is positive. Table 2 also presents the relative lengths
of the bounds compared to the ZR’s. Under Assumptions 1–4, the width of the bounds is
reduced by 77.2% even with a conservative specification ρ > 0, showing that the detailed
survival information helps narrow the bounds on the SACE.
The underlying distribution of this hypothetical example describes a scenario where the
commonly assumed monotonicity assumption in the previous literature is violated. Under
the above specification with ρ = 0.6, the proportions of always survivors, protected, harmed,
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Table 3
Bounds on the SACE for the numerical example in Section 1.1 under two different sets of assumptions:
Assumptions 1–3, and Assumptions 1 with ZR’s ranked average score assumptions in (4) and (5).
ρ log(φ) Bounds Relative Length
0.000 0.000 [0.118, 0.299] 0.228
0.100 0.301 [0.134, 0.284] 0.188
0.200 0.607 [0.146, 0.271] 0.158
0.300 0.926 [0.156, 0.261] 0.132
0.400 1.264 [0.165, 0.256] 0.115
0.500 1.632 [0.173, 0.152] 0.099
0.600 2.049 [0.182, 0.248] 0.084
0.700 2.545 [0.191, 0.246] 0.069
0.800 3.189 [0.200, 0.243] 0.055
0.900 4.191 [0.210, 0.242] 0.041
0.990 7.110 [0.218, 0.241] 0.029
0.999 9.773 [0.219, 0.241] 0.028
0.9999 12.331 [0.219, 0.241] 0.028
ZR [−0.147, 0.647] 1.000
and never survivors are 0.519, 0.081, 0.181 and 0.219, respectively. When the monotonicity
assumption does not hold, YS’s bounds may or may not include the true effect. In this
example, applying YS’s bounds by utilizing time point 4’s (a post measurement time point)
survival information, the bounds on the SACE are [0.188, 0.298] which cover the true effect.
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Table 4
Risks of the bad HRQOL outcome for each fine stratum with Si(1) = t1 and Si(0) = t0 under treatment (qt1t01) and
under control (qt1t00) in the numerical example in Section 1.2. The risks are presented in the form of qt1t01(qt1t00),
with “−” indicating that the corresponding risk is not defined.
❅
❅
❅
❅
❅
t1
t0
0 1 2 3 4
0 − (−) − (−) − (0.70) − (0.55) − (0.40)
1 − (−) − (−) − (0.70) − (0.55) − (0.40)
2 0.75 (−) 0.75 (−) 0.75 (0.55) 0.70 (0.40) 0.65 (0.25)
3 0.70 (−) 0.70 (−) 0.70 (0.50) 0.65 (0.35) 0.60 (0.20)
4 0.60 (−) 0.60 (−) 0.60 (0.45) 0.55 (0.20) 0.50 (0.15)
8.2 Additional numerical example showing the consequence with incorrectly assumed
monotonicity assumption
We show an example in which YS’s method produces bounds that exclude the true effect,
and therefore lead to biased result. Let us still consider a hypothetical study where subjects
are followed up four times (K = 4) at time points 1, 2, 3, and 4 with equal follow-up intervals
and the HRQOL outcome is measured at the second follow-up (T = 2). We set the marginal
distributions pitd = P{S(d) = st} for t = 0 to 4 and d = 0, 1 as follows:
pi01 = 0.30, pi11 = 0.40, pi21 = 0.15, pi31 = 0.10, pi41 = 0.05,
pi00 = 0.40, pi10 = 0.30, pi20 = 0.15, pi30 = 0.10, pi40 = 0.05.
As before, given the marginal distributions, we specify their joint distribution by a Plack-
ett copula with φ = 7.76, corresponding to a Spearman correlation ρ = 0.6. Under this
setup, the proportions of always survivors, protected, harmed, and never survivors are
0.182, 0.118, 0.118 and 0.582, respectively. The underlying risks of developing the bad
HRQOL outcome under treatment and under control for each fine stratum are described
in Table 4.
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Table 5
Bounds on the SACE for the numerical example in Section 1.2 under various sets of assumptions.
SACE Without Monotonicity Monotonicity
Assumptions 1–3 Assumptions 1 with
ZR’s ranked average score assumptions
0.267 ρ = 0.0 [0.010, 0.477] [−0.485, 0.685] 0.200
ρ = 0.2 [0.049, 0.460]
ρ = 0.6 [0.155, 0.351]
ρ = 0.9 [0.178, 0.277]
In the above setup, SACE = 0.267, meaning that the treatment increases the risk of the
bad HRQOL outcome by 0.267 among patients who will survive at least to time point 2
under both treatment arms.
Suppose that we have an infinite sample. Under Assumption 1 in the main paper, we
would observe the values of pitd’s since pitd = P (Si = st | Di = d), and would observe the
joint distribution of Yi and Si in each treatment arm,
P (Yi = 1, Si = 2 | Di = 1) = 0.110, P (Yi = 1, Si = 3 | Di = 1) = 0.067,
P (Yi = 1, Si = 4 | Di = 1) = 0.028, P (Yi = 1, Si = 2 | Di = 0) = 0.091,
P (Yi = 1, Si = 3 | Di = 0) = 0.042, P (Yi = 1, Si = 4 | Di = 0) = 0.012.
Table 5 presents the bounds on the SACE under various sets of assumptions. With a
conservative assumption that ρ > 0, the bounds on the SACE are [0.010, 0.477] under our
generalized ranked average score assumptions, whereas ZR’s ranked average score assump-
tions provide a much wider bounds [−0.485, 0.685] that are not informative. Both methods
do not invoke the monotonicity assumption, and the bounds obtained correctly cover the
true effect. In contrast, if we incorrectly impose the monotonicity assumption and apply YS’s
method by utilizing time point 4’s survival information, we would conclude that the SACE is
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0.200 which is 25% smaller than the true effect 0.267. The monotonicity assumption results
in degenerate bounds in this example. This is because when there are no harmed subjects,
the proportion of the protected is equal to the difference between the proportions of subjects
survived to the measurement of the HRQOL outcome under treatment and under control,
which is 0 in this example. Then there is no uncertainty in each subject’s principal strata’s
membership: everyone survived to the second follow-up time point is an always survivor, and
everyone died before the second follow-up time point is a never survivor.
9. The details of the optimization problem we solve for the SWOG study
Given the values of pi1, pi0, α21, α31, α20, α30 drawn from their posterior distribution
described in the Section 5 of the main paper and the value of the copula parameter φ, we
first obtain the values of the joint probabilities of the survival times under treatment and
under control pt1t0 ’s where pt1t0 = P (Si(1) = st1 , Si(0) = st0). In the SWOG study, recall
that K = 3, T = 2, and s0 = 0, s1 = 3, s2 = 6, s3 = 12. Then, viewing qt1t0d’s as unknown
variables, we solve the following linear programming problem:
min /max
∑3
t1=2
∑3
t0=2
(qt1t01 − qt1t00)pt1t0∑3
t1=2
∑3
t0=2
pt1t0
Subject to :
3∑
t1=0
pt1t0qt1t00 = pit00αt00, for t0 = 2, 3
3∑
t0=0
pt1t0qt1t01 = pit11αt11, for t1 = 2, 3.
0 6 qt1t0d’s 6 1
qt1t01 6 qt′1t′01, for all 2 6 t
′
1 6 t1 6 3 where st1 + st0 > st′1 + st′0
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qt1t00 6 qt′1t′00, for all 2 6 t
′
0 6 t0 6 3 where st1 + st0 > st′1 + st′0
10. Results on the SWOG study using the Gaussian copula
Let Fd(·) be the marginal distribution function for the random variable Si(d) with Fd(st) =
P{Si(d) 6 st} (d = 0, 1). The joint distribution function F (st1 , st0) of Si(1) and Si(0) linked
by the Gaussian copula is given by Cr(F1(st1), F0(st0)), where
Cr(u, v) = Φr(Φ
−1(u),Φ−1(v)).
In the expression above, Φ−1 is the inverse of the standard normal cumulative distribution
function, Φr is the joint cumulative distribution function of a bivariate normal distribution
with mean vector zero and covariance matrix equal to the correlation matrix


1 r
r 1

. The
parameter r measures the Pearson correlation between the random variables Si(1) and Si(0),
and the Spearman correlation coefficient ρ between Si(1) and Si(0) is a monotonic function
of r: ρ = 6
pi
· arcsin( r
2
).
We now replace the Plackett copula with the Gaussian copula in the analysis to evaluate the
sensitivity of the results to the choice of the type of copula. Table 6 compares the estimated
bounds and the 95% credible intervals under our generalized ranked average score assump-
tions (i.e., Assumptions 1–3) by modeling the joint distribution of the potential survival
times under DE and MP (i) using the Plackett copula, and (ii) using the Gaussian copula.
The results are robust to the choice of the type of copula. For instance, with a correlation
ρ > 0.2 between the two potential survival times under DE and MP, under the Gaussian
copula, the estimated bounds are [−0.098,−0.008] (compared to [−0.099,−0.008] under the
Plackett copula) with a 95% credible interval [−0.216, 0.107] (compared to [−0.216, 0.106]
under the Plackett copula).
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Table 6
Results for the SWOG study under our generalized ranked average score assumptions comparing the Plackett copula with the Gaussian copula.
ρ Estimated Bounds 95% Credible Interval
Plackett Gaussian Plackett Gaussian
0.0000 [−0.110, 0.005] [-0.110, 0.005] [−0.226, 0.128] [-0.226, 0.128]
0.1000 [−0.105,−0.002] [-0.105, -0.002] [−0.222, 0.116] [-0.221, 0.117]
0.2000 [−0.099,−0.008] [-0.098, -0.008] [−0.216, 0.106] [-0.216, 0.107]
0.3000 [−0.092,−0.015] [-0.092, -0.014] [−0.204, 0.103] [-0.205, 0.101]
0.4000 [−0.085,−0.020] [-0.085, -0.020] [−0.194, 0.095] [-0.196, 0.095]
0.5000 [−0.077,−0.025] [-0.077, -0.025] [−0.187, 0.086] [-0.186, 0.089]
0.6000 [−0.070,−0.029] [-0.071, -0.029] [−0.180, 0.080] [-0.177, 0.085]
0.7000 [−0.065,−0.031] [-0.066, -0.031] [−0.174, 0.078] [-0.170, 0.082]
0.8000 [−0.062,−0.033] [-0.062, -0.033] [−0.167, 0.079] [-0.168, 0.079]
0.9000 [−0.059,−0.037] [-0.059, -0.036] [−0.168, 0.073] [-0.166, 0.075]
0.9900 [−0.053,−0.042] [-0.053, -0.042] [−0.162, 0.069] [-0.163, 0.069]
0.9990 [−0.052,−0.043] [-0.052, -0.043] [−0.161, 0.069] [-0.161, 0.069]
0.9999 [−0.052,−0.043] [-0.052, -0.043] [−0.161, 0.069] [-0.161, 0.069]
